TickerFacts.

Company research / VRTX

Vertex Pharmaceuticals Inc (VRTX)

Build a valuation ↗↓ Download CSV

SEC name VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated MA
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Vertex Pharmaceuticals Inc reported revenue of $12.00B. Revenue grew 8.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $12.59B.

Key ratios (year ended 2025-12-31)

86.2%
Gross margin (computed)
34.8%
Operating margin
32.9%
Net margin
21.2%
Return on year-end equity
8.9%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-20

Headquarters locality: Boston · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$12.59B$12.00B$11.02B$9.87B$8.93B$7.57B$6.21B$4.16B$3.05B$2.49B$1.70B
Cost of Revenue$1.76B$1.65B$1.53B$1.26B$1.08B$904.20M$736.30M$547.80M$409.54M$275.12M$210.46M
Gross Profit (computed)$10.82B$10.35B$9.49B$8.61B$7.85B$6.67B$5.47B$3.62B$2.64B$2.21B$1.49B
R&D Expense$3.91B$3.91B$3.63B$3.16B$2.54B$1.94B$1.64Bn/an/an/an/a
Operating Income$4.78B$4.17B-$232.90M$3.83B$4.31B$2.78B$2.86B$1.20B$635.15M$123.24M$9.94M
Depreciation & Amortization$222.10M$209.80M$207.20M$181.30M$148.30M$125.60M$109.50M$106.90M$72.42M$61.40M$61.40M
EBITDA$5.00B$4.38B-$25.70M$4.01B$4.46B$2.91B$2.97B$1.30B$707.57M$184.64M$71.33M
Net Income$4.41B$3.95B-$535.60M$3.62B$3.32B$2.34B$2.71B$1.18B$2.10B$263.48M-$112.05M
EPS (Diluted)n/a$15.32-$2.08$13.89$12.82$9.01$10.29$4.51$8.09$1.04-$0.46
Total Assets$27.42B$25.64B$22.53B$22.73B$18.15B$13.43B$11.75B$8.32B$6.25B$3.55B$2.90B
Total Liabilities$7.18B$6.98B$6.12B$5.15B$4.24B$3.33B$3.06B$2.23B$1.81B$1.50B$1.56B
Shareholders' Equity$20.25B$18.67B$16.41B$17.58B$13.91B$10.10B$8.69B$6.09B$4.44B$2.03B$1.16B
Cash & Equivalents$6.14B$5.08B$4.57B$10.37B$10.50B$6.79B$5.99B$3.11B$2.65B$1.67B$1.18B
Operating Cash Flow$4.29B$3.63B-$492.60M$3.54B$4.13B$2.64B$3.25B$1.57B$1.27B$844.94M$236.10M
Capital Expenditures$496.80M$437.60M$297.70M$200.40M$204.70M$235.00M$259.80M$75.40M$95.45M$99.42M$56.56M
Free Cash Flow$3.80B$3.19B-$790.30M$3.34B$3.93B$2.41B$2.99B$1.49B$1.17B$745.52M$179.54M
Share Repurchases$2.01B$2.02B$1.18B$427.60M$0$1.43B$539.10M$186.00M$350.04M$0$0
Shares Outstanding253.35M253.99M256.94M257.70M257.01M254.48M259.89M258.99M255.17M253.25M248.30M
Weighted Average Diluted Sharesn/a258.00M257.90M260.50M259.10M259.90M263.40M260.70M259.19M253.22M244.69M
EPS (Basic)n/a$15.46-$2.08$14.05$12.97$9.09$10.44$4.58$8.24$1.06-$0.46

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView